 |
 |
 |
 |
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
 |
 |
 |
|
|
|
|
|
 |
  
 
|
|
 |
| |
|
| |
|
| |
|
Drugs
|
Trimester of weeks
|
Adverse Effects
|
|
Captopril |
1,2,3
|
May adversely affect fetal and
neonatal blood pressure control and renal function. |
|
Diazoxide |
2,3
|
Prolonged use may produce alopecia
and impaired glucose tolerance in the neonate. Inhibits uterine
activity during labour. |
|
Reserpine |
3
|
Neonatal bradycardia, drowsiness
and nasal stuffiness. |
| (e)
Vasodilators |
|
|
|
Nifedipine |
3
|
Calcium antagonists may inhibit
labour |
| (f) Vasoconstrictors |
|
|
| Noradrenaline |
1,2,3
|
Avoid - may reduce placental
perfusion |
| (g) Anticoagulants |
|
|
|
Heparin |
1,2,3
|
Osteoporosis has been reported
after prolonged use |
|
Oral anticoagulants |
1,2,3
|
Congenital malformations. Fetal
and neonatal hemorrhage. Subcutaneous heparin should be substituted
in the last few weeks of pregnancy in deepvein thrombosis |
| (h)
Fibrinolytic drugs |
|
|
| Streptokinase,
Urokinase |
1,2,3
|
Possibility of premature separation
of placenta in first 18 weeks. Theoretical possibility of fetal
haemorrhage throughout pregnancy. Avoid postpartum use - maternal
haemorrhage. |
| (i)
Antifibrinolytic drugs |
|
|
| Aminocaproic
acid |
1,2,3
|
Avoid - may increase the risk
of thrombosis |
(j)
Drugs used in
hyperlipidaemia |
|
|
| Clofibrate,
Probucol |
1,2,3
|
Avoid - theoretical
possibility of interference with embryonic growth and development
due to anticholesterol effect. |
|
|
| |
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
| |
|
|
|
|
